NCT03958045View on ClinicalTrials.gov

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

Rucaparib and Nivolumab

Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)

Trial Locations (1)

40536

Markey Cancer Center, University of Kentucky, Lexington

Sponsors

Collaborators (1)

Clovis Oncology, Inc.

All Listed Sponsors

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Zhonglin Hao

OTHER